Eliem Therapeutics (ELYM) Competitors

Eliem Therapeutics (NASDAQ:ELYM) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Which has more volatility and risk, ELYM or TNGX?

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Do analysts rate ELYM or TNGX?

Tango Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 774.70%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tango Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to ELYM or TNGX?

In the previous week, Tango Therapeutics had 6 more articles in the media than Eliem Therapeutics. MarketBeat recorded 6 mentions for Tango Therapeutics and 0 mentions for Eliem Therapeutics. Tango Therapeutics' average media sentiment score of 1.34 beat Eliem Therapeutics' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Tango Therapeutics	Positive

Which has better valuation & earnings, ELYM or TNGX?

Eliem Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	-2.53
Tango Therapeutics	$42.07M	3.62	-$101.74M	-$1.21	-1.17

Do insiders & institutionals have more ownership in ELYM or TNGX?

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 6.3% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is ELYM or TNGX more profitable?

Eliem Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. Eliem Therapeutics' return on equity of -47.03% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Tango Therapeutics	-284.42%	-49.64%	-32.00%

Does the MarketBeat Community prefer ELYM or TNGX?

Tango Therapeutics received 20 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 74.36% of users gave Tango Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.

Company	Underperform	Outperform
Eliem Therapeutics	Outperform Votes 9 56.25%	Underperform Votes 7 43.75%
Tango Therapeutics	Outperform Votes 29 74.36%	Underperform Votes 10 25.64%

Summary

Tango Therapeutics beats Eliem Therapeutics on 13 of the 17 factors compared between the two stocks.